Buprenorphine: clinical use

Prescribing considerations

• Confirm the indication and formulation: selected patches are analgesic products; Buvidal is for opioid dependence within comprehensive care.
• Agree treatment goals and a discontinuation plan; assess misuse, dependence, diversion, accidental exposure and concurrent sedatives.
• When initiating or switching to Buvidal, consider the risk of precipitated withdrawal after recent full-agonist opioid exposure.
• Plan separately for acute pain or procedures because strong receptor binding can complicate full-agonist opioid analgesia.
• Assess respiratory, hepatic, neurological and substance-use risks; use additional caution with severe renal impairment and relevant QT-prolongation risks.

Contraindications and cautions

• All selected products: hypersensitivity to buprenorphine or product excipients.
• Selected pain patches: severe impairment of respiratory function, current or recent MAO-inhibitor treatment, myasthenia gravis, delirium tremens, pregnancy, and use for opioid-dependence withdrawal treatment.
• Buvidal: severe respiratory insufficiency, severe hepatic impairment, acute alcoholism or delirium tremens.

Monitoring

• Clinical response, sedation and respiratory status, particularly after treatment changes or with interacting depressants.
• Signs of opioid use disorder, misuse, diversion, tolerance, hyperalgesia or withdrawal.
• Hepatic function and evidence of toxicity or withdrawal in hepatic impairment; Buvidal recommends regular hepatic monitoring.
• Sleep-related breathing problems, seizure risk and orthostatic hypotension where relevant.
• Patch adhesion and skin reactions; for Buvidal, inspect injection sites for infection, abscess, ulceration or necrosis.

Clinical pharmacology

Buprenorphine is a high-affinity, slowly dissociating partial mu-opioid agonist and kappa-opioid antagonist. It is extensively metabolised in the liver, principally through CYP3A4-mediated N-dealkylation and glucuronidation; prolonged-release formulations produce sustained systemic exposure.

Formulation and product differences

• Relevtec and Bupeaze are transdermal matrices licensed for specified severe pain. Absorption is gradual and can increase with fever or external heat.
• Selected patch products differ in construction and appearance; follow individual product instructions rather than assuming brands are identical.
• Buvidal is a prolonged-release subcutaneous depot for opioid dependence, administered only by a healthcare professional. Intravascular, intramuscular or intradermal administration can cause serious harm.
• Buvidal's prolonged persistence must be considered when managing adverse effects, interactions, treatment interruption, surgery or discontinuation.

Injection

Route: Parenteral

Strengths: 8 mg, 16 mg, 24 mg, 32 mg, 64 mg, 96 mg, 128 mg, 160 mg